In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat

Executive Summary

Epizyme Inc. assigned Royalty Pharma the future royalty streams on Japanese sales of tazemetostat (an oral EZH2 inhibitor candidate for both solid tumors and hematological malignancies). In exchange, Epizyme could receive as much as $570mm in financing, with up to a $200mm equity investment from Royalty Pharma and up to $370mm in debt financing from Pharmakon Advisors, a Royalty Pharma affiliate. Epizyme has appointed a representative from Royalty Pharma to its board.

Deal Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Royalty Sale

Related Companies